Glycoprotein iib-/iiia receptor blockers (overview)

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Glycoprotein IIb/IIIa receptors are altered in their conformation by stimulators such as thrombin, ADP, thrombaxane, collagen, platelet activating factors and adrenaline and express high-affinity fibrinogen binding sites. This is where the blocking drugs attack. GPIIb/IIIa antagonists used in the clinic are monoclonal antibodies.

Currently on the market are:

  • Abcimiximab
  • Eptifibatide
  • Tirofiban

LiteratureThis section has been translated automatically.

  1. HA Neumann (2014) The coagulation system. ABW-Scientific Publisher GmbH Berlin

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer